Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” studyMathias Jachs, Péter Ferenci, Elmar Aigner et al.|Alimentary Pharmacology & Therapeutics|2022Cited by 73
Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosisMathias Jachs, Thomas Reiberger, Heidemarie Holzmann et al.|United European Gastroenterology Journal|2021Cited by 32
Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppressionMathias Jachs, Péter Ferenci, Mattias Mandorfer et al.|JHEP Reports|2023Cited by 27